Dana-Farber Cancer Institute | Strategic Alliance Partners

George D. Demetri, MD, expands on the challenges with overall survival as a primary outcome measure, the potential of trabectedin in soft tissue sarcomas, and the significance of a recent trial.

Limited clinical evaluation suggests a potentially major role for immune checkpoint inhibition in the treatment of lymphomas, but early success has also raised many questions.

Molecular profiling of every patient with acute myelogenous leukemia may hold the key to better treatment in the future.

Trabectedin demonstrated superior disease control compared with dacarbazine in heavily pretreated patients with advanced soft tissue sarcoma.

Charles S. Fuchs, MD, discusses a recent study which found that consuming four or more cups of coffee per day may reduce risk of recurrence by 42% and death by 34% in patients with stage III colon cancer.

Research evidence has been mounting that PARP inhibitors are not just for gynecologic malignancies-or for patients whose tumors harbor inherited BRCA defects.

Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

Blockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.

Treatment with telotristat etiprate significantly reduced the average number of daily bowel movements compared with placebo for patients with carcinoid syndrome that was not adequately controlled with a somatostatin analog.

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

George D. Demetri, MD, Director, Center for Sarcoma and Bone Oncology Senior Vice President for Experimental Therapeutics, Professor of Medicine, Harvard Medical School, Dana Farber Cancer Center, discusses a phase III study of trabectedin verus dacarbazine for the treatment of patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses adding platinum-based therapy to the neoadjuvant setting for the treatment of patients with triple-negative breast cancer.

A new drug application has been submitted for the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma

Although BRCA1/2 mutations have been intensely studied in breast cancer for more than a decade, researchers are still seeking to determine which patient populations should be screened for abnormalities and how best to integrate that information into treatment protocols.

Treatment with inotuzumab ozogamicin demonstrated a complete response (CR) or CR with incomplete platelet recovery rate of 80.7% in patients with relapsed or refractory acute lymphoblastic leukemia.

Robert J. Mayer, MD, discusses pivotal phase III results for TAS-102 in colorectal cancer.

Combination therapy has significant potential to fill the niche of developing resistance to BTK inhibitors and rational pairings of ibrutinib with other standard treatments, including chemoimmunotherapy and CD20-targeting monoclonal antibodies (mAbs) are rapidly gaining ground.

As the field evolves, it is likely that HER2-directed agents will be used to an increasing extent instead of conventional chemotherapy, further reducing toxicity.

Charles S. Fuchs, MD, discusses the impact of the approval of ramucirumab in metastatic colorectal cancer and what further research is needed for the optimal utilization of the VEGFR-2 inhibitor.

Treatment with the oral nucleoside TAS-102 (tipiracil hydrochloride) demonstrated a significant improvement in overall survival compared with placebo for patients with refractory metastatic colorectal cancer.

Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute discusses combining immunotherapies in myeloma.

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses how oncologists can treat patients with metastatic renal cell carcinoma (mRCC) based off of findings from a study that looked at the impact of body mass index (BMI) on outcomes of these patients.

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances in chronic lymphocytic leukemia (CLL) treatment.

To gain insight into the integration of olaparib into clinical practice, OncLive interviewed Ursula A. Matulonis, MD, medical director of gynecologic oncology at Dana-Farber Cancer Institute.

The only therapeutic cancer vaccine ever to win approval from the FDA has repeatedly missed sales projections, plunging the company that developed it into bankruptcy proceedings.

The treatment of patients with multiple myeloma is poised to undergo a dramatic transformation, as novel monoclonal antibodies and combination strategies race toward approval.

The addition of the GM-CSF agent sargramostim to the CTLA-4 inhibitor ipilimumab (Yervoy) prolonged overall survival (OS) and lowered toxicity for patients with unresectable stage III or IV melanoma

A novel first-in-class covalent KRAS inhibitor SML-8-73-1 has demonstrated promise in preclinical studies, prompting a 3-year research collaboration between the Dana-Farber Cancer Institute and Astellas Pharma Inc.